![Christopher Kenney](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Christopher Kenney
Chief Tech/Sci/R&D Officer at
XENON PHARMACEUTICALS INC.
Net worth: 386 886 $ as of 2026-05-30
Profile
Christopher Kenney is currently the Chief Medical Officer at Xenon Pharmaceuticals, Inc. He previously held positions as the Senior Vice President-Medical Affairs at Acorda Therapeutics, Inc. from 2018 to 2019, the Chief Medical Officer at Cadent Therapeutics, Inc. from 2019 to 2020, and the Senior Vice President-Clinical Development at Biotie Therapies LLC from 2013 to 2016.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2026-04-06 | 7,069 ( 0.01% ) | 386 886 $ | 2026-05-30 |
Christopher Kenney active positions
| Companies | Position | Start |
|---|---|---|
| XENON PHARMACEUTICALS INC. | Chief Tech/Sci/R&D Officer | 2021-08-22 |
Former positions of Christopher Kenney
| Companies | Position | End |
|---|---|---|
Cadent Therapeutics, Inc.
 Cadent Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops novel small molecule therapeutics to treat schizophrenia and other cognitive disorders | Chief Tech/Sci/R&D Officer | 2020-11-30 |
| ACORDA THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 2018-12-31 |
Biotie Therapies, Inc. | Chief Tech/Sci/R&D Officer | 2015-12-31 |
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
16
1st degree connections
4
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 4 |
|---|---|
Acorda Therapeutics, Inc.
 Acorda Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops neurology therapies | Health Technology |
Xenon Pharmaceuticals, Inc.
 Xenon Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Engages in discovering, developing and delivering of therapeutics for neurological & psychiatric disorders | Health Technology |
Cadent Therapeutics, Inc.
Cadent Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops novel small molecule therapeutics to treat schizophrenia and other cognitive disorders | Health Technology |
Biotie Therapies, Inc. |
- Stock Market
- Insiders
- Christopher Kenney
